The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: Implications for a new "pill-in-pocket" approach in structural heart disease

Journal of Atrial Fibrillation

Volumn 2, Issue 1, 2010, Pages 705-710

  Murdock, David K ^a,b,c   Reiffel, James A ^d   Kaliebe, Jeff ^b   Larrain, German ^a,b,c  

^a Cardiovascular Associates of Northern Wisconsin   (United States)

^b CaRE Foundation Inc   (United States)

^c Aspirus Wausau Hospital   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anti arrhythmic agents; Anti arrhythmic therapy; Atrial fibrillation; Conversion; Ranolazine

Indexed keywords

PLACEBO; RANOLAZINE;

AGED; AORTA STENOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONSTIPATION; CORONARY ARTERY DISEASE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HOME; HOSPITAL; HUMAN; MALE; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SINUS RHYTHM;

EID: 77957864855     PISSN: None     EISSN: 19416911     Source Type: Journal    
DOI: 10.4022/jafib.v2i1.572     Document Type: Article

References (34)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469-473.
2. Brodsky MA, Chun JG, Podrid PJ, et al. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med. 1996;156(22):2553-62.
3. Lown B, Amarasingham R, and Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge, JAMA 182 (1962), pp. 548-555.6;156:2553-2562.
4. G.E. Kochiadakis, N.E. Igoumenidis and M.C. Solomou et al. Efficacy of amiodarone for the termination of persistent atrial fibrillation, Am J Cardiol 83 (1999), pp. 58-61.
5. Capucci, G. Boriani and I. Rubino, et al. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm, Int J Cardiol 43 (1994), pp. 305-313.
6. M.L. Sedgwick, G. Lip and A.P. Rae et al., Chemical cardioversion of atrial fibrillation with intravenous dofetilide, Int J Cardiol 49 (1995), pp. 159-166.
7. M.J. Suttorp, J.H. Kingma and A.H. Lie et al., Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm, Am J Cardiol 63 (1989), pp. 693-696.
8. Borgeat, J.J. Goy and R. Maendly et al., Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm, Am J Cardiol 58 (1986), pp. 496-498.
9. A.S. Volgman, P.A. Carberry and B. Stambler et al., Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation, J Am Coll Cardiol 31 (1998), pp. 1414-1419.
10. Azpitarte J, Alvarez M, Baun O, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation: Results of a randomized, double-blind, controlled study, Eur Heart J 18 (1997), pp. 1649-1654. (Pubitemid 27412422)
11. Alboni P, Botto GL, Baldi N, et al. Outpatient Treatment of Recent-Onset Atrial Fibrillation with the "Pill-in-the-Pocket" Approach. N Engl J Med 2004; 351(23): 2384-2391.
12. Capucci A, Villani GQ, Piepoli MF et al. The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation, Curr Opin Cardiol 14 (1999), pp. 4-8.
13. Capucci A, Boriani G, Botto GL, et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994;74:503-505.
14. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:446.
15. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331:785-91.
16. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-666.
17. Haghjoo M. Efficacy, safety, and role of segmental superior vena cava isolation in the treatment of atrial fibrillation. Electrocardiol. 2007;40:327.e1. (Pubitemid 46962000)
18. Knecht S, O'Neill MD, Matsuo S, et al. Focal arrhythmia confined within the coronary sinus and maintaining atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:1140-6.
19. Wit AL, Boyden PA: Triggered activity and atrial fibrillation. Heart Rhythm. 2007;4(3 Suppl):S17-23.
20. Zhou S, Chang CM, Wu TJ, et al. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol 2002;283: H1244-H1252.
21. Chen YJ, Chen SA, Chen YC et al. Electrophysiology of single cardiomyocytes isolated from rabbit pulmonary veins: Implication in initiation of focal atrial fibrillation. Basic Res Cardiol 2002;97: 26-34.
22. Patterson E, Po SS, Scherlag BJ, et al. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm 2005;2: 624-631.
23. Ono N, Hayashi H, Kawase A, et al. Spontaneous atrial fibrillation initiated by triggered activity near the pulmonary veins in aged rats subjected to glycolytic inhibition. Am Physiol Heart Circ Physiol. 2007;292:H639-48.
24. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J. 2006 Suppl A1, A10-A13.
25. Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192-9. (Pubitemid 38982162)
26. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007; 116:1449-57.
27. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-10.
28. Undrovinas AI, Belardinelli L, Undrovinas NA, et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17 Suppl 1:S169-S177.
29. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-83.
30. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-52.
31. Murdock DK, Kaliebe J, Overton N. Ranolozine-Induced Suppression of Ventricular Tachycardia in a Patient with Nonischemic Cardiomyopathy: A Case Report. Pacing and Clinical Electrophysiology. 2008; 31 (6): 765-768. (Pubitemid 351749321)
32. Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol. J. 2008;8(3):175-181.
33. Murdock DK, Kersten M, Kaliebe J, Larrain G, The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol. J. 2009; 9(5): 260-267.
34. Reiffel, JA. Cardioversion for atrial fibrillation: treatment options and advances. PACE 2009; 32:1073-84.